Immediate administration of zoledronic acid reduces aromatase inhibitorassociated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trial

Clinical Breast Cancer

Volumn 12, Issue 1, 2012, Pages 40-48

  Llombart, Antonio ^a,b   Frassoldati, Antonio ^c   Paija, Outi ^d   Sleeboom, Harm Peter ^e   Jerusalem, Guy ^f   Mebis, Jeroen ^g   Deleu, Ines ^h   Miller, Joel ⁱ   Schenk, Nora ⁱ   Neven, Patrick ^j  

^a INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^b HOSPITAL ARNAU DE VILANOVA   (Spain)

^c UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^d TURKU UNIVERSITY HOSPITAL   (Finland)

^e HAGA HOSPITAL   (Netherlands)

^f CHU SART TILMAN   (Belgium)

^g Jessa Ziekenhuis   (Belgium)

^h AZ Nikolaas   (Belgium)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j UNIVERSITY HOSPITALS LEUVEN   (Belgium)

more..

Author keywords

Aromatase inhibitor; Bone mineral density; Early breast cancer; Letrozole; Postmenopausal; Zoledronic acid

Indexed keywords

AROMATASE INHIBITOR; HORMONE RECEPTOR; LETROZOLE; ZOLEDRONIC ACID;

ADJUVANT THERAPY; ADULT; AGED; ANXIETY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BONE DENSITY; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DEPRESSION; DOSAGE SCHEDULE COMPARISON; DRUG SAFETY; EARLY CANCER; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; FRACTURE; HEADACHE; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FAILURE; LYMPHEDEMA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MYALGIA; NAUSEA; OSTEOLYSIS; PERIPHERAL EDEMA; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SHOULDER PAIN; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84862926420     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.08.002     Document Type: Article

References (39)

1. R.W. Carlson, D.C. Allred, B.O. Anderson Breast cancer Clinical practice guidelines in oncology J Natl Compr Canc Netw 7 2009 122 192
2. B. Thuerlimann, D. Koeberle, H.J. Senn Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: past, present and future recommendations Eur J Cancer 43 2007 46 52 (Pubitemid 46084847)
3. R.W. Carlson, C.A. Hudis, K.I. Pritchard Adjuvant endocrine therapy in hormone receptorpositive postmenopausal breast cancer: evolution of NCCN, ASCO, and St Gallen recommendations J Natl Compr Canc Netw 4 2006 971 979 (Pubitemid 44845487)
4. P. Hadji Aromatase inhibitorassociated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis Crit Rev Oncol Hematol 69 2009 73 82
5. S. Aebi, T. Davidson, G. Gruber Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21 suppl 5 2010 v9 v14
6. A. Howell, J. Cuzick, M. Baum Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer Lancet 365 2005 60 62
7. B. Thurlimann, A. Keshaviah, A.S. Coates A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer N Engl J Med 353 2005 2747 2757 (Pubitemid 43016814)
8. H. Mouridsen, A. Giobbie-Hurder, A. Goldhirsch Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer N Engl J Med 361 2009 766 776
9. R.E. Coleman, L.M. Banks, S.I. Girgis Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study Lancet Oncol 8 2007 119 127 (Pubitemid 46158372)
10. H.J. Burstein, A.A. Prestrud, J. Seidenfeld American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptorpositive breast cancer J Clin Oncol 28 2010 3784 3796
11. N.J. Bundred Aromatase inhibitors and bone health Curr Opin Obstet Gynecol 21 2009 60 67
12. M.F. Gnant, B. Mlineritsch, G. Luschin-Ebengreuth Zoledronic acid prevents cancer treatmentinduced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group J Clin Oncol 25 2007 820 828 (Pubitemid 350002882)
13. E.S. Siris, Y.T. Chen, T.A. Abbott Bone mineral density thresholds for pharmacological intervention to prevent fractures Arch Intern Med 164 2004 1108 1112 (Pubitemid 38668990)
14. E.S. Siris, S.K. Brenneman, P.D. Miller Predictive value of low BMD for 1-year fracture outcomes is similar for postmenopausal women ages 50-64 and 65 and older: results from the National Osteoporosis Risk Assessment (NORA) J Bone Miner Res 19 2004 1215 1220 (Pubitemid 41094361)
15. D. Marshall, O. Johnell, H. Wedel Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures BMJ 312 1996 1254 1259 (Pubitemid 26147662)
16. M. Gnant, B. Mlineritsch, G. Luschin-Ebengreuth Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy Lancet Oncol 9 2008 840 849
17. A. Brufsky, W.G. Harker, J.T. Beck Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer J Clin Oncol 25 2007 829 836 (Pubitemid 350002883)
18. N.J. Bundred, I.D. Campbell, N. Davidson Effective inhibition of aromatase inhibitorassociated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results Cancer 112 2008 1001 1010 (Pubitemid 351304583)
19. A.M. Brufsky, L.D. Bosserman, R.R. Caradonna Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results Clin Breast Cancer 9 2009 77 85
20. H. Eidtmann, R. de Boer, N. Bundred Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study Ann Oncol 21 2010 2188 2194
21. ® (zoledronic acid) injection [prescribing information] 2011 Novartis Pharmaceuticals Corporation East Hanover, NJ
22. WHO Scientific Group on the Prevention and Management of Osteoporosis Prevention and Management of Osteoporosis: Report of a WHO Scientific Group WHO Technical Report Series 921 http://whqlibdoc.who.int/trs/WHO-TRS-921.pdf Accessed: March 1, 2011
23. National Osteoporosis Foundation Clinician's Guide to Prevention and Treatment of Osteoporosis http://www.nof.org/sites/default/files/pdfs/NOF- ClinicianGuide2009-v7.pdf Accessed: March 1, 2011
24. National Cancer Institute Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events v3.0 (CTCAE) http://ctep.cancer.gov/ protocolDevelopment/electronic-applications/docs/ctcaev3.pdf Accessed: March 1, 2011
25. R. Weitzman, N. Sauter, E.F. Eriksen Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patientsMay 2006 Crit Rev Oncol Hematol 62 2007 148 152 (Pubitemid 46575276)
26. A.M. Brufsky Cancer treatment-induced bone loss: pathophysiology and clinical perspectives Oncologist 13 2008 187 195 (Pubitemid 351342583)
27. T. Saarto, C. Blomqvist, M. Valimaki Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients J Clin Oncol 15 1997 1341 1347 (Pubitemid 27167365)
28. C.L. Shapiro, J. Manola, M. Leboff Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer J Clin Oncol 19 2001 3306 3311 (Pubitemid 32642182)
29. P. Hadji, J.J. Body, M.S. Aapro Practical guidance for the management of aromatase inhibitor-associated bone loss Ann Oncol 19 2008 1407 1416
30. R.C. Coombes, L.S. Kilburn, C.F. Snowdon Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial Lancet 369 2007 559 570
31. M. Gnant, B. Mlineritsch, W. Schippinger Endocrine therapy plus zoledronic acid in premenopausal breast cancer N Engl J Med 360 2009 679 691
32. P.E. Goss, J.N. Ingle, S. Martino Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 J Natl Cancer Inst 97 2005 1262 1271 (Pubitemid 41535367)
33. R. Eastell, C. Van Poznak, R.A. Hannon The SABRE (Study of Anastrozole with the Bisphosphonate RisedronatE) study: 12-month analysis J Bone Miner Res 22 suppl 1 2007 S113 abstract 300
34. J.E. Lester, D. Dodwell, O.P. Purohit Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer Clin Cancer Res 14 2008 6336 6342
35. G.K. Ellis, H.G. Bone, R. Chlebowski Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer J Clin Oncol 26 2008 4875 4882
36. M. Gnant, B. Mlineritsch, H. Stoeger et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomized trial Lancet Oncol 12 2011 631 641
37. Brufsky A, Harker G, Beck JT, et al. The effect of zoledronic acid on aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: the Z-FAST study 5-year final follow-up. Poster presented at 32nd Annual San Antonio Breast Cancer Symposium. San Antonio, Texas; 2009: abstract 4083.
38. R.E. Coleman, M.C. Winter, D. Cameron The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer Br J Cancer 102 2010 1099 1105
39. R.E. Coleman, H. Marshall, D. Cameron Breast-cancer adjuvant therapy N Engl J Med 2011 10.1056/NEJMoa1105195 [E-pub ahead of print]